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Polymyxins are last-resort antibiotics for treating infections of Gram-negative bacteria. The recent 
emergence of polymyxin-resistant bacteria, however, urgently demands clinical optimisation 
of polymyxin use to minimise further evolution of resistance. In this study we developed a novel 
combination therapy using minimal concentrations of polymyxin B. After large-scale screening of 
Streptomyces secondary metabolites, we identified a reliable polymixin synergist and confirmed 
as netropsin using high-pressure liquid chromatography, nuclear magnetic resonance, and mass 
spectrometry followed by in vitro assays using various Gram-negative pathogenic bacteria. To evaluate 
the effectiveness of combining polymixin B and netropsin in vivo, we performed survival analysis on 
greater wax moth Galleria mellonella infected with colistin-resistant clinical Acinetobacter baumannii 
isolates as well as Escherichia coli, Shigella flexineri, Salmonella typhimuruim, and Pseudomonas 
aeruginosa. The survival of infected G. mellonella was significantly higher when treated with polymyxin 
B and netropsin in combination than when treated with polymyxin B or netropsin alone. We propose 
a netropsin combination therapy that minimises the use of polymyxin B when treating infections with 
multidrug resistant Gram-negative bacteria.
Life-threatening bacterial infections are a major concern in health care settings worldwide. Because of increase 
in the emergence of antibiotic resistant bacteria, medical practitioners must look to rarely used antibiotics for 
alternative treatment options1,2. For instance, bacteria such as Acinetobacter baumannii cause nosocomial infec-
tions in immunocompromised patients, which, until recently, could be effectively treated with carbapenems3. The 
recent emergence of carbapenem-resistant Gram-negative pathogenic bacteria, such as A. baumannii, Escherichia 
coli, Pseudomonas aeruginosa, and Klebsiella pneumonia, has led to the resurgence of polymyxins as last-resort 
antibiotic treatments3–5. Multidrug resistant (MDR) A. baumannii infections are associated with intensive care 
units and are implicated in ventilator associated pneumonia and urinary tract infections4. In the recent times 
MDR A. baumannii are reported to exhibit a variety of resistance mechanisms to most classes of antibiotics which 
demands immediate development of new therapies6.
Polymyxins are cataionic lipopeptide antibiotics produced by non-ribosomal peptide synthetase enzyme 
complexes and are bactericidal agents with a detergent-like mechanism of action7. Colistin (polymixin E) and 
polymixin B are the two important forms of polymixnis with clinical significance8. They have largely been used 
in topical form as otic and ophthalmic solutions and are also used in combination with numerous other anti-
biotics, such as carbapenems, efflux pump inhibitors, β -lactamase inhibitors, and wall teichoic acid synthesis 
inhibitors7–10. However, the use of polymyxins is limited by their nephrotoxic and neurotoxic effects and hence 
administered mostly to prevent rather than treat infections11,12. Furthermore, the pharmacokinetics and pharma-
codynamics of polymyxin B remain poorly understood. In addition, there has been a surge in reports of infections 
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caused by naturally-occurring, polymyxin-resistant bacteria, including Providencia spp., Proteus spp., Morganella 
spp., and Serretia spp.4 There is thus urgency to optimise the clinical use of polymixins by designing effective 
combination therapies11,12.
In the present study, we conducted a large-scale screening of secondary metabolites isolated from Streptomyces 
spp. and assessed their synergistic potential when combined with polymyxin B. The most effective secondary 
metabolite was identified as netropsin. Combination therapy consisting of polymyxin B and netropsin showed 
synergistic effects when tested on Gram-negative bacteria in vitro, including clinical isolates of colistin (pol-
ymyxin E)-resistant A. baumannii. The effectiveness of the combination therapy was verified in vivo using 
G. mellonella as a model host organism. Netropsin is a pyrrole-amide antitumor drug that binds preferentially 
to AT-rich regions in the minor groove of DNA and increases positive supercoiling13,14. Thus, the molecular 
specificity of netropsin makes it a versatile molecule for use not only against bacteria, but also potentially against 
viruses and tumors15.
Results
Development of novel screening system to identify antibiotics enhancing agents. Certain anti-
biotics such as polymixins are poor diffusing bactericidal agents on agar medium and hence difficult to obtain 
consistent results using traditional disc diffusion tests. Here we developed liquid media-based screening tech-
nique to screen for novel compounds that show synergetic effects with polymixin B. The strategy of mining 
antimicrobial agents from secondary metabolites library, their subsequent identification and evaluation both 
in vitro and in vivo is detailed in a step-by-step procedure (Fig. 1). a. Isolation of Streptomyces spp. from different 
soil environment. b. Construction of 1800 metabolite library from each isolated Streptomyces sp. c. Mass screen-
ing of metabolites with polmyxin B to test synergetic effects on E. coli. d. Identification of synergetic compound 
and bacteria producing the compound. e. In vitro checkerboard assay. f. Time kill assay using the greater wax 
moth infection model.
Identification of compounds that enhance the antibiotic activity of polymixin B. To identify 
substances capable of enhancing the antibacterial action of polymyxin B, a strategy using a massive library of 1800 
secondary metabolites isolated from equal number of Streptomyces spp. culture samples was established (Fig. 1a). 
A collection of 1800 strains of Streptomyces spp. were isolated from various soil samples that were obtained 
from forest, land, compost, and river water in S. Korea. Humic-vitamin medium was used for selective isola-
tion of Streptomyces spp., which was then maintained as pure culture glycerol stocks. Glucose-Starch-Soybean 
(GSS) meal medium was used for activating secretory secondary metabolites produced from corresponding 
Streptomyces spp. culture stocks (Fig. 1b). Combinatorial effect of individual secondary metabolites with different 
concentrations of polymixin B was tested by measuring physiological change of E. coli oxidative metabolism as 
indicated by 0.5% tetrazolium dye (indicating oxygen consumption) (Fig. 1c). Of the extracts tested, an extract 
AN130070 showed the greatest synergistic effect at a minimum inhibitory concentration (MIC) of 0.25 mg/L of 
polymyxin B (Fig. S1). A checkerboard assay using serially diluted AN130070 metabolite with 0.25 mg/L pol-
ymixin B showed maximum synergy at zero dilution of AN130070 (Fig. S1). To identify the bacterial source 
of AN130070, genomic DNA of the corresponding stock was isolated and subjected to 16s rDNA sequencing. 
NCBI BLAST search of the sequence revealed that AN130070 metabolite was produced by S. netropsis SN01 
(Fig. S2)16,17.
Analysis of AN130070 by HPLC and MS. To identify the compounds responsible for the antibacterial 
activity of AN130070, a series of chemical fractionations were conducted. After each round, fractions were tested 
for synergy with polymyxin B to enhance bioactive fractions. Eight of 27 fractions (RB625B-12, 13, 19~24) were 
initially selected through C18HPLC to show synergism with polymyxin B. Compound 1 (RB625B-12A), obtained 
from RB625B-12 sub-fractions of AN130070 that is taken from the butanol layer exhibited synergistic effects with 
polymyxin B (Fig. S3). The Compound 1 was further analysed by HPLC to determine their chemical identity. UV 
absorption peak of the Compound 1 showed similar retention time compared with that of reference (commercial 
netropsin) (Fig. 2a). The 1H NMR inspection confirmed chemical structure of the Compound 1 compared with 
1H NMR data of netropsin (Fig. S4)18. MS spectrum analysis of the Compound 1 from AN130070 extracted from 
S. netropsis SN01 showed two major peaks at m/z 431.2264 and 431.2291, and was consistent with the known 
spectrum for netropsin (Fig. 2b)17,18.
Checkerboard assay for synergistic activity against Gram-negative bacteria. The MIC values of 
polymyxin B against several Gram-negative bacteria were lowered by adding netropsin, which indicated synergy. 
The bacteria tested included E. coli MG1655 and A. baumannii ATCC15150 that are a commensal bacterium 
and a human pathogen respectively. The fractional inhibitory concentration index (FICI) was then calculated 
to estimate the strength of the synergism. The FICI was 0.375 for E. coli MG1655 and 0.25 for A. baumannii 
ATCC15150, indicating strong synergism between netropsin and polymyxin B (Table 1). To test the practical 
application of a combination therapy using polymixin B and netropsin, a checkerboard assay was performed 
against clinical isolates of A. baumannii YCSAb5 and YCSAb7 that were obtained from Yonsei Severance Hospital, 
Seoul, S. Korea. For both isolates of A. baumannii YCSAb5 and YCSAb7, the FICI value was 0.375, showing syn-
ergism. In total 6 of 7 strains of A. baumannii showed FICI < 1.
Colistin (also referred to as polymyxin E) and polymyxin B are the same class peptide antibiotics and share 
similar structures and physicochemical properties. To test the combination of polymyxin B and netropsin against 
colistin-resistant, clinical isolates of A. baumannii, a checkerboard assay was carried out on five isolates. On 
colistin-resistant A. baumannii YCRAb257, the synergism was strong, with a FICI value of 0.266. Results with 
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other isolates YCRAb 49, 269, 301 and 615 also indicated partial synergism of the polymyxin B and netropsin 
combination (Table 1).
The checkerboard assay was conducted for other Gram-negative bacteria- S. flexneri SF2a, S. typhimurium 
LT2, and P. aeruginosa PA14 and its clinical isolate YPa2. For S. flexneri SF2a and S. typhimurium LT2, there was 
partial synergism, with FICI values of 0.75 and 0.625, respectively (Table 1). When compared with the MICs of 
SF2a using polymyxin B alone and netropsin alone, the combination of netropsin with polymyxin B yielded 8- 
and 2-fold decrease in MICs, respectively. The FICI values for PA14 and YPa2 were 1 and 1.003, which indicated 
lack of synergism.
Combination therapy using the greater wax moth, an alternative animal model. We verified the 
results obtained above by performing a survival assay in G. mellonella infected with A. baumannii ATCC1515019. 
Figure 1. Large-scale screening strategy of secondary metabolites for mining agents that enhance the action 
of polymyxin B. A to F. Schematic representation of each experimental procedure to identify and characterize 
compounds that show synergism with polymyxin B. (a) Isolation of various Streptomyces spp. from different 
soil environmental samples. (b) Isolation of secondary metabolites from individual Streptomyces spp. (c) Mass 
screening of metabolites with serial concentrations of polmyxin B (250, 25, 2.5 and 0 mg/L), as indicated by 
violet color shades. Tetrazolium dye (0.5%) is included along with media, to measure the E. coli susceptibility 
to combined action of secondary metabolite and polymixin B. (d) Identification of synergetic compounds that 
originated from selected metabolite using 16 s rDNA sequencing and analytical chemistry techniques to identify 
compound within the metabolite responsible for synergism. (e) Checkerboard assay to test synergistic activity 
of compounds present in secondary metabolites against various Gram-negative pathogenic bacteria. (f) In vivo 
time kill assay using the greater wax moth to verify the effectiveness of combination therapy. Bacterial strains 
were infected to G. mellonella larvae followed by administration of polymixin B or netropsin or both.
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Polymyxin B and netropsin treatment concentrations were calculated from the MICs determined by in vitro 
assays. Concentrations of 0.5 mg/L of polymyxin B and 100 mg/L of netropsin were identified as the lowest active 
concentrations based on MIC values under in vitro conditions. The survival of G. mellonella was higher after 
24 hours under treatment with the combination therapy (90%) than it was when polymyxin B (66.7%) or netrop-
sin (76.67%) were administered individually. In addition, the survival of G. mellonella treated with the combina-
tion therapy was higher than that of untreated insects (46.7%; Fig. 3a).
Two clinical A. baumannii isolates YCSAb5 and YCSAb7 were tested in vivo for efficacy of combination ther-
apy (Fig. 3b,c). The combination treatment exhibited potent synergism (YCSAb5, 40% and YCSAb7, 36.7%) as 
compared to polymyxin B (YCSAb5, 10% and YCSAb7, 26.7%) or netropsin (YCSAb5, 10% and YCSAb7, 10%) 
monotherapy 24 hours after treatment (Fig. 3b,c).
The combination therapy was also tested against five clinical isolates of colistin-resistant A. baumannii. We 
used the concentrations of single or double antibiotics to 4 mg/L of polymyxin B and 12.5 mg/L of netropsin 
based on Table 1. A. baumannii isolates YCRAb49, YCRAb257, and YCRAb615 showed relatively higher survival 
after 12 hours when treated with the combination therapy (YCRAb49, 60%; YCRAb257, 53.3%; and YCRAb615, 
73.3%) than when treated with individual antibiotics (Fig. 4d,e,h). With YCRAb 269, the effects of the combina-
tion therapy lasted for 24 hours after treatment, and survival was higher (43.3%) than it was under monotherapy 
(polymyxin B, 23.3% and netropsin, 26.7%; Fig. 4f). However, the effect of the combination therapy on YCRAb 
301 was not significantly different than that of monotherapy (Fig. 4g). A combination therapy using colistin and 
Figure 2. Identification of Netropsin. (a) HPLC spectrum of Compound 1 from AN130070 metabolite (left) 
and netropsin (right). Inner panel presented UV absorption of each peaks originated from subfraction of 
AN130070. RB625B12;Varian C18 column; 5~30% MeCN for 20 min, ~60% MeCN for 30 min, ~100% MeCN 
for 5 min, wash for 10 min, flow rate 1 mL/min, detection by absorption at 297 nm (b) Mass spectrum (positive 
ESI mode) of Compound 1 (Hao et al. 2013).
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netropsin was also evaluated. In contrast to the combination of polymixin B and netropsin, the combination of 
colistin and netropsin did not exhibit a synergistic effect, except in the case of A. baumannii ATCC 15150 and 
YCRAb615 (Fig. S5).
Next, we tested the effectiveness of combination of polymyxin B and netropsin against other Gram-negative 
pathogenic bacteria (Fig. 4). The combination therapy resulted in 30% and 23.3% higher survival than monother-
apy when used against S. flxneri SF2a (polymyxin B 10% and netropsin 0%) and S. typhimurium LT2 (polymyxin 
B 0% and netropsin 0%) infection, respectively (Fig. 4a,b). In the case of P. aeruginosa PA14 infection, there was 
no difference in survival under combination therapy (0%) compared to monotherapy or the control (0%; Fig. 4c). 
However the survival of G. mellonella inoculated with these clinical isolates was higher under treatment with 
combination therapy (80%) than when treated with monotherapy (polymyxin B 20% and netropsin 3.3%) or the 
untreated control (0%) in the case of P. aerugnosa YPa2 (Fig. 4d).
Discussion
In this study, a novel combination therapy consisting of a last resort antibiotic (polymixin B) and an antitumor 
and antiviral drug (netropsin) is developed as an antimicrobial recipe against drug-resistance bacteria through 
in vitro screening of Streptomyces spp. secondary metabolites followed by in vivo evaluation (Fig. 1). Standard 
disc diffusion technique for polymixin susceptibility test is unreliable due to slow diffusion of polymixins on 
agar medium20. Here we utilized highly sensitive tetrazolium dye-based detection of synergism between natural 
compounds and polymixin B that allowed us to minimize antibiotic usage in the combination therapy. Bacterial 
secondary metabolites are the gold mine of antibiotics and are produced mainly by Streptomyces spp. in the idi-
ophase21. We found that one of the metabolite among the screens; AN130070 is majorly composed of netropsin 
that markedly enhanced combinatorial effect with polymixin B against E. coli. Mono-treatment of AN130070 
metabolite did not show significant inhibition, suggesting a potential adjuvant activity of netropsin (Fig. S1). The 
combination therapy was most effective against clinical isolates of A. baumannii wherein 6 out of 7 isolates tested 
showed FICI < 1 including colistin resistant isolates (Table 1). Presently colistin (polymyxin E) and polymixin B 
are the only two most clinically relevant polymixins with nearly identical spectrum of activity20. Despite similar-
ities in the mechanism of action and toxicity between colistin and polymixin B, chemical structure, formulation, 
dosage and pharmacokinetic properties vary to a considerable extent between the two biochemical agents22. In 
our study, polymixin-netropsin combination therapy was effective against colistin resistant clinical isolates of A. 
baumannii with FICI < 0.5 (Table 1) and the colistin-netropsin therapy did not show same improvement, indi-
cating that efficacy of combination therapy depends on formulation of type of polymixin used with netropsin 
(Figs 3 and S5). In addition, since the efficacy of colistin mono-therapy is low against colistin-resistant isolates, a 
combination therapy of colistin and netropsin can require further in vivo optimization that may vary from that of 
polymixin B-netropsin combination therapy22.
As such, role of netropsin has been primarily attributed to its antitumor and antiviral properties23. The cres-
cent shaped molecule binds to the AT rich region of the DNA minor grove, thus inhibiting cellular processes such 
as replication, transcription and thus killing the aggressively dividing cancer cells rapidly24. The mechanism of 
action of netropsin has been extensively studied in the past13,14,25. Netropsin affects positive supercoiling of DNA 
















A. baumanii, clinical isolates (YCSAb5, 7), and colistin resitant clinical isolates (YCRAb49, 257, 269, 301, 615) 
 A. baumannii ATCC15150 0.25 2 0.25 0.001953–0.5 200 25 3.125–100
 A. baumanii YCSAb5 0.375 1 0.25 0.125–0.25 200 25 3.2–100
 A. baumanii YCSAb7 0.375 2 0.25 0.125–1 200 50 12.5–100
 A. baumanii YCRAb49 0.75 16 8 8 800 200 200–400
 A. baumanii YCRAb257 0.266 16 4 0.125–2 200 3.125 12.5–100
 A. baumanii YCRAb269 0.508 8 4 0.25–2 400 3.125 3.125–100
 A. baumanii YCRAb301 0.508 8 4 0.5–2 400 3.125 3.125–200
 A. baumanii YCRAb615 0.508 8 4 0.125–2 400 3.125 3.125–200
Commensal and human pathogenic Gram-negative bacteria 
 E. coli MG1655 0.375 1 0.125 0.0625–0.125 50 12.5 0.098–25
 S. flexneri SF2a 0.75 1 0.25 0.125–0.5 12.5 6.25 3.125–6.25
 S. typhimurium LT2 0.625 4 0.5 0.250–0.5 25 12.5 6.25–12.5
 P. aeruginosa PA14 1 1 0.5 0.5–1 400 200 400–200
 P. aeruginosa YPa2 1.004 2 2 2 800 3.125 800
Table 1.  In vitro MIC and FICI values for treatments against Gram-negative bacterial strains. 
Abbreviations: Com, the most inhibitory concentration (MIC) value of combined antibiotics; FICI, fractional 
inhibitory concentration index; FICIpolB/net indicates the values at the most synergistic combination of polymyxin 
B and netropsin; MIC, minimum inhibitory concentration; net, netropsin; polB, polymyxin B; MICpolB/net and  
MICnet/polB represent the series of MIC values of polymyxin B or netropsin in the presence of netropsin or 
polymyxin B except the MIC values of monotherapy, respectively. FICI = MIC(A2)/MIC(A1) + MIC(B2)/
MIC(B1). All MIC values are in mg/L.
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some report suggests that netropsin alone do not significantly inhibit bacterial growth26. Of all the species tested, 
A. baumannii ATCC15150 showed highest synergy of FICI 0.25, while strains of P. aeruginosa showed FICI 1. 
Figure 3. Synergistic effects of polymyxin B combination with netropsin against A. baumannni and its 
clinical isolates. The survival of G. mellonella infected with A. baumannii, its clinical isolates (YCSAb5 and 
YCSAb7), and colistin resistant clinical isolates (YCRAb49, 257, 269, 301, 615). (a) A. baumanii ATCC 15150, 
(b) YCSAb2, (c) YCSAb7, (d) YCRAb 49, (e) YCRAb 257, (f) YCRAb 269, (g) YCRAb 301, and (h) YCRAb 615. 
Treatments were: polymyxin B 4 mg/L (▲ ), netropsin 12.5 mg/L(△ ), polymyxin B 4 mg/L + netropsin 12.5 mg/L 
(■ ), control (○ ), and mock (● ). Results represent means of three independent determinations ± standard 
deviations for 20 insects per treatment. An asterisk (* ) indicates a significant difference between combination 
and monotherapy (p < 0.05).
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The variations in the FICI values among different species tested are attributed to species-specific breakpoints of 
polymixin MIC values20. In particular, high efficacy against A. baumannii clinical isolates (FICI < 0.5) is of utmost 
clinical significance since polymyxin resistant A. baumannii are on a global rise at an alarming rate3,4. Overall, the 
decrease in the MIC of polymyxin B-netropsin combination therapy is statistically significant when compared to 
the reversed counterpart treatment.
The observed synergy was effective and consistent in the G. mellonella host. Few ethical constraints, a short 
life-cycle, and an innate immune response similar to that of higher vertebrates led us to use G. mellonella as an 
attractive model host19. Polymyxin B and netropsin combination therapy increased the survival of G. mellonella 
infected with A. baumannii upto 80% compared to survival without antibiotic treatment (Fig. 3). Monotherapies 
of polymixin B and netropsin showed lesser survival in most of the clinical isolates of A. baumannii and P. aerugi-
nosa YPa2 compared to the combination therapy suggesting in vivo efficacy of the combination therapy (Figs 3b,c 
and 4d). Variation in survival number of individual positive controls of clinical isolates is reflected in the efficacy 
of the combination therapy. We did not see significant efficacy in case of P. aeruginosa Pa14 both in vitro and 
in vivo (Table 1, Fig. 4). In a pharmacokinetic study involving P. aeruginosa infection in G. mellonella larvae, 
little therapeutic benefit was seen treated with colistin27. Notably, there are no documented studies that show 
suitability of G. mellonella in studying combination therapies against Gram-negative bacteria. Treatment, opti-
mization, and evaluation in clinically relevant model hosts are currently being explored to further develop the 
polymixin-netropsin combination therapy. Polymyxin B has been used in combination with numerous other 
antibiotics, such as carbapenems, efflux pump inhibitors, β -lactamase inhibitors, and wall teichoic acid synthesis 
inhibitors10. However, less clinical experience with polymixin B usage and resuscitation of polymixin resistant 
pathogenic strains demands more robust combination therapies, which minimize the use of multiple antibiotics20.
Figure 4. Synergistic effects of polymyxin B combination with netropsin. The survival of G. mellonella 
infected with (a) S. flexneri SF2a, (b) S. typhimurium LT2, (c) P. aeruginosa PA14 and (d) clinical isolates of 
P. aeruginosa YPa2 at 12 and 24 hour post-infection. Treatments were: polymyxin B 0.5 mg/L (▲ ), netropsin 
100 mg/L (△ ), polymyxin B 0.5 mg/L + netropsin 100 mg/L (■ ), control (○ ), and mock (● ). Results represent 
means of three independent determinations ± standard deviations for 20 insects per treatment. An asterisk  
(* ) indicates a significant difference between combination and monotherapy (p < 0.05).
www.nature.com/scientificreports/
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Off late polymixin B usage is increasingly promoted in the human health care. For example, a 3.5-year study 
extensively evaluated the clinical efficacy and safety profile of of polymixin B mono- and combination therapy for 
the respiratory tract infections caused by MDR P. aeruginosa and A. baumannii28. Of the 25 patients administered 
with 29 courses of polymixin B, 76% displayed favorable response while 52% survived the hospitalization with 
minimal nephro- and neurotoxcity. A total of 41% achieved microbiological clearance and only 21% displayed 
end-of-treatment mortality. Similarly more experiences that evaluate polymixin B with new adjuvants and ther-
apeutic agents are required to minimize the dosage and maximize the effectiveness of the polymixin B combina-
tion therapy.
Presently, there are no DNA-binding, antibacterial agents qualified for clinical trial. Polymyxins have high 
affinity for lipopolysaccharides, as they competitively displace divalent cations from the bacteria’s outer mem-
brane20,29. This allows transient uptake of a variety of molecules, leading to changes in membrane permeability 
and, ultimately, cell death7,30. Therefore, we speculate that polymyxin B enhances netropsin uptake through the 
outer membrane, thereby increasing the binding of netropsin to bacterial DNA and inhibiting cell growth7,20. 
However, this speculated model seems to have species-specific limitations. For example, synergy was not signifi-
cant in case of P. aeruginosa both in vitro and in vivo (Table 1, Fig. 4) which could be attributed to highly evolved 
efflux pump systems and increased outer membrane impermeability that may render polymixin B and netropsin 
combination therapy ineffective31. Nevertheless, to the best of our knowledge, this is the first study to investi-
gate in vivo efficacy of a DNA-binding antitumor agent with polymyxin B against Gram-negative bacteria that is 
demonstrated using the clinical MDR isolates of A. baumannii.
In conclusion, the combination therapy of polymxin B and netropsin provides a potential alternative to the 
existing limitations of polymixin usage and polymixin resistance. Mass screening of secondary metabolites iso-
lated from Streptomyces spp. is a simple and effective method and hosts a plethora of useful compounds that are 
effective against a number of drug resistant, Gram-negative bacterial species including polymyxin B and colistin 
resistant A. baumannii. By using 96-well-containing tetrazolium dye-based in vitro high throughput screening 
and G. mellonella-based time kill studies we have demonstrated for the first time the efficacy of this novel combi-
nation therapy against polymixin B and colistin resistant clinical isolates of Gram-negative pathogenic bacteria.
Methods
Ethical considerations. Under the Korean Law of ‘Bioethics and Safety’, we had verbal approval from the 
hospital IRB committee to use the bacterial isolates from clinical samples without informed consents if we elim-
inated all the patients’ identifiers. The Committee approved all the experimental protocols using clinical isolates. 
All experimental procedures and methods were carried out in accordance with the approved protocols and the 
Committee’s guidelines.
Bacterial strains and media. E. coli MG1655, A. baumannii ATCC15150, P. aeruginosa strain PA14, 
Shigella flexneri SF2a, and Salmonella typhimurium LT2 were grown in Luria-Bertani (LB) broth at 37 °C. Clinical 
specimens were isolated from blood, sputum, and faeces of patients suffering from P. aeruginosa YPa2, A. bauma-
nii YCSAb5, and YCSAb7 infections. Clinical isolates of colistin-resistant A. baumannii YCRAb49, 257, 269, 301, 
and 615 were analysed in the hospital (Yonsei Severance Hospital, Seoul, S. Korea) and were grown at 37 °C in LB 
medium or agar (Asan Company) and Muller-Hinton agar (Asan Company)32,33.
Construction of Streptomyces spp. secondary metabolite library. 1800 of Streptomyces spp. 
were isolated from various soil samples that were obtained from forest, land, compost, and river water in 
S. Korea (http://www.mrscc.net). One gram wet weight of each soil sample was suspended in 9 ml of saline solu-
tion, serially diluted down to 10−6, and aliquots of each dilution (100 μl) was plated on humic-vitamin agar34, or 
fivefold-diluted R2A agar35, all supplemented with cycloheximide (50 μg/ml) to reduce fungal contamination. 
Sample dilution plates were incubated at 28 °C for 14~21 days until sporulated or non-sporulated Streptomyces 
sp. colonies were observed and morphologically distinct colonies were isolated (Fig. 1a). A total of 1800 pure 
bacterial cultures were maintained on Bennett’s agar (10 g glucose, 1 g yeast extract, 2 g peptone, 1 g beef extract 
and 15 g of agar per liter; pH 7.0) and stored as 20% (v/v) glycerol suspensions at − 80 °C. Individual bacterial 
samples were then inoculated into GSS liquid medium (10 g soluble starch, 20 g glucose, 25 g soybean meal, 1 g 
beef extract, 4 g yeast extract, 2 g NaCl, 0.25 g K2HPO4 and 2 g CaCO3 per liter; pH 7.2) to activate secondary 
metabolites secreted from correspondent Streptomyces sp. isolates and incubated at 28 °C with continuous shaking 
for 5–7 days at 140 rpm (Fig. 1b). Cultures were centrifuged at 10000 rpm and the supernatant was collected as the 
source of secretory secondary metabolite and stored at − 4 °C for future use.
Mass screening of secondary metabolites. A total of 50 μ L of the individual secondary metabolites 
isolated from respective culture broths of Streptomyces spp. were added to 100 μ L Muller-Hinton (MH) broth 
of minimal media containing 250, 25, 2.5, or 0 mg/L of polymyxin B and 0.5% tetrazolium dye as an indicator 
for oxidatively physiological change in individual wells of 96-well plates. After inoculation with 0.5% of a fresh 
culture of E. coli strain MG1655 (O.D.600 = 0.3), the plates were incubated at 37 °C. The survival of MG1655 was 
determined by checking the colour change into violet (alive) or dead (transparent) and by measuring the OD600 nm 
in a spectrophotometer (Fig. 1c). Selected metabolites were tested in triplicate. The checkerboard assay with pol-
ymyxin B and secreted metabolite from selected AN130070 was conducted to optimize the serial concentration 
of polymyxin B (1, 0.5, 0.25, 0.125, 0.625, 0.031, 0.016, and 0 mg/L) with serially diluted AN130070 metabolite 
(1, 0.5, 0.25, 0.13, 0.06, and 0; 5 dilution factors from initial concentration of AN130070 metabolite produced 
from S. netropsis SN01) (Fig. S1)36.
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Chemical fractionation of AN130070. A culture (10 L) of strain S. netropsis AN130070 was extracted 
three times with butanol (5.0 L). The extracts were combined and concentrated under reduced pressure to yield 
19.0 g of dark brown gel. The gel was fractionated on a reversed-phase middle pressure liquid chromatography 
(MPLC) (Teledyne Isco, HP C18 Aq. Redisef Rf gold, 40 id × 300 mm; flow rate 7 mL/min, 100% H2O for 60 min, 
~50% aq. MeOH for 300 min, MPLC 2. 50~100% MeOH for 300 min, wash for 60 min), yielding 27 sub-fractions. 
Sub-fractions 12 (120 mg, a brown gel) was purified by repeated, preparative C18 HPLC (Microsorb 100-5, C18, 
21.4 id × 250 mm; gradient elution of 10 to 25% aqueous MeCN for 30 min, flow rate: 7 mL/min; detection by 
absorption at 297 nm) to afford Compound 1 (1.2 mg, tR 33.0 min) (Figs 1d and S3).
Identification of netropsin. NMR spectra were recorded on a Varian Mercury 400 spectrometer with 
standard pulse sequences operating at 400 MHz in 1H NMR. Chemical shifts measured in ppm, were referenced 
to solvent peak (δ H 3.31 for CD3OD). Compound 1; 1H NMR(CD3OD, 400 MHz): δ 7.19 (1 H, s), 7.17 (1 H, s), 6.90 
(1 H, s), 6.89 (1 H, s), 4.06 (2 H, s), 3.89 (3 H, s), 3.87 (3 H, s), 3.65 (2 H, m), 2.72 (2 H, s). High Resolution-ESI-MS 
spectra were recorded in the positive ESI (electrospray ionization) mode using a Waters SYNAPT G2 at the Korea 
Basic Science Institute. HR-TOF-MS (positive ESI mode) m/z 432.2264 [M + H]+ (calculated for C18H27N10O3+, 
431.2262) (Fig. 1d).
16S rRNA gene sequencing. Genomic DNA from the strain was prepared using the method by Tamaoka 
and Komagata37. The 16S rRNA gene was amplified by PCR with the forward primer 27F and the reverse primer 
1492R16. Direct sequence determination of the PCR amplified DNA was carried out using an automated DNA 
sequencer (model ABI 3730XL, Applied Biosystems). The 16S rRNA gene sequence of the strain was compared 
with available sequences from GenBank using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/) to 
determine an approximate phylogenetic affiliation, and sequence similarity values were computed using the 
EzTaxon server (http://www.eztaxon.org/) (Fig. 1d)38.
In vitro MIC tests. The checkerboard assay as in vitro assay was performed using commercially available 
netropsin in combination with polymyxin B (Fig. 1e). The initial concentrations of each antibiotic were deter-
mined from previously determined MIC90 values39–41. Wells containing the lowest fractional inhibitory concen-





where A1 is the MIC value of antibiotic A monotherapy, A2 is the MIC value of antibiotic A combination therapy, 
B1 is the MIC value of antibiotic B monotherapy, and B2 is the MIC value of antibiotic B combination therapy). 
Synergistic effects were defined in terms of FICI values as ≤ 0.5 (perfect synergy), > 0.5 to < 1 (partial synergy), a 
value of 1 (additive effect), and > 1 (loss of synergism). MIC values were interpreted as previously described36,42. 
MICpol/net range value were determined the series of concentration of first-indicated antibiotics (polymyxin) con-
centration range in the presence of the second-indicated antibiotics (netropsin) showing synergism in the check-
erboard assay in Table 1 (opposite to MICnet/pol)9.
G. mellonella time kill assay. To confirm the synergism of polymyxin B with netropsin in vivo, time kill 
assay of greater wax moth, Galleria mellonella, as a model system were carried out (Fig. 1f). G. mellonella caterpil-
lars were grown at 37 °C until they reached the fourth larval instar (Ecowin). Caterpillars were then stored in the 
dark at 37 °C for 3 days for stabilization. Bacterial cells were washed with phosphate-buffered saline and diluted 
to 106 cfu/larva. Bacterial inocula were injected into the left and right abdominal cavities of 20 randomly selected 
larvae using 5 μ L micro-syringes (MicroliterTM #701, Hamilton). Within 30 min of infection with the microbial 
suspension, monotherapy or combination therapy was performed on the caterpillars by injecting antibiotic into 
different prolegs. The amount of antibiotic (polymyxin B and netropsin, Sigma) administered to individual cat-
erpillars was determined by larval weight and MIC results from the in vitro assay. Infected caterpillars were kept 
in a 37 °C incubator to assess survival 12 and 24 hours after inoculation43. All experiments were repeated thrice.
Data analysis. All experiments were repeated thrice. The results were reported as the mean ± SD from at 
least three representative experiments. Statistical analyses were carried out with JMPIN 4.0.4 (SAS Institute) 
using one-way ANOVA followed by a Student’s t-test for treatment comparisons. Differences were considered to 
be significant at p < 0.05.
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